Matches in SemOpenAlex for { <https://semopenalex.org/work/W2358717605> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2358717605 abstract "The phosphatidylinositide 3-kinases (PI3Ks) have emerged as important therapeutic targets for the treatment of solid and hematological malignancies. In solid tumor therapy, the majority of clinical activity has centered on pan-class I (p110alpha, beta, delta and gamma) inhibitors of limited selectivity, or pan-class I/mTOR dual inhibitors, whereas targeting p110delta and p110gamma has been the main focus for hematological cancer treatment. Our research at Karus has focused on the emerging role of p110beta and p110delta in both cancer types, though increasingly in solid tumors, in which overexpression, mutation and PTEN-defectiveness have been shown to be key features in disease pathogenesis and progression. We have designed and developed a uniquely-selective series of orally-active molecules that inhibit the p110beta/delta isoforms, and which display extremely high specificity in the human kinome. The design of such molecules has enabled us to interrogate the function of p110delta in solid tumor immunotherapy and p110beta in primary tumor growth and metastasis, with our lead compounds showing promising oral activity in syngeneic models, in which they inhibit tumor growth and metastatic spread whilst also impacting on downstream biomarker levels. Additionally, through our ability to tune selectivity over p110alpha and p110gamma, elimination of the mechanism-related toxicities associated with those isoforms can be realized, making selective dual p110beta/delta inhibition, described herein for our lead compound, KA2237, potentially more conducive to combination therapy than for pan-inhibitors, including with signal transduction pathway inhibitors and other immunotherapeutics. KA2237, an orally-active, potent and selective small molecule p110beta/delta inhibitor, has completed GLP toxicology and will enter Phase I studies in 2015. Citation Format: Stephen Shuttleworth. Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition and anti-metastatic activity. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B115." @default.
- W2358717605 created "2016-06-24" @default.
- W2358717605 creator A5037370563 @default.
- W2358717605 date "2015-12-01" @default.
- W2358717605 modified "2023-10-14" @default.
- W2358717605 title "Abstract B115: Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition and anti-metastatic activity" @default.
- W2358717605 doi "https://doi.org/10.1158/1535-7163.targ-15-b115" @default.
- W2358717605 hasPublicationYear "2015" @default.
- W2358717605 type Work @default.
- W2358717605 sameAs 2358717605 @default.
- W2358717605 citedByCount "0" @default.
- W2358717605 crossrefType "proceedings-article" @default.
- W2358717605 hasAuthorship W2358717605A5037370563 @default.
- W2358717605 hasConcept C121608353 @default.
- W2358717605 hasConcept C126322002 @default.
- W2358717605 hasConcept C184235292 @default.
- W2358717605 hasConcept C203014093 @default.
- W2358717605 hasConcept C2777609662 @default.
- W2358717605 hasConcept C2777701055 @default.
- W2358717605 hasConcept C502942594 @default.
- W2358717605 hasConcept C54174078 @default.
- W2358717605 hasConcept C62478195 @default.
- W2358717605 hasConcept C71924100 @default.
- W2358717605 hasConcept C86554907 @default.
- W2358717605 hasConcept C86803240 @default.
- W2358717605 hasConcept C8891405 @default.
- W2358717605 hasConcept C95444343 @default.
- W2358717605 hasConcept C98274493 @default.
- W2358717605 hasConceptScore W2358717605C121608353 @default.
- W2358717605 hasConceptScore W2358717605C126322002 @default.
- W2358717605 hasConceptScore W2358717605C184235292 @default.
- W2358717605 hasConceptScore W2358717605C203014093 @default.
- W2358717605 hasConceptScore W2358717605C2777609662 @default.
- W2358717605 hasConceptScore W2358717605C2777701055 @default.
- W2358717605 hasConceptScore W2358717605C502942594 @default.
- W2358717605 hasConceptScore W2358717605C54174078 @default.
- W2358717605 hasConceptScore W2358717605C62478195 @default.
- W2358717605 hasConceptScore W2358717605C71924100 @default.
- W2358717605 hasConceptScore W2358717605C86554907 @default.
- W2358717605 hasConceptScore W2358717605C86803240 @default.
- W2358717605 hasConceptScore W2358717605C8891405 @default.
- W2358717605 hasConceptScore W2358717605C95444343 @default.
- W2358717605 hasConceptScore W2358717605C98274493 @default.
- W2358717605 hasLocation W23587176051 @default.
- W2358717605 hasOpenAccess W2358717605 @default.
- W2358717605 hasPrimaryLocation W23587176051 @default.
- W2358717605 hasRelatedWork W13418166 @default.
- W2358717605 hasRelatedWork W13524344 @default.
- W2358717605 hasRelatedWork W24597417 @default.
- W2358717605 hasRelatedWork W27973947 @default.
- W2358717605 hasRelatedWork W29497872 @default.
- W2358717605 hasRelatedWork W37096307 @default.
- W2358717605 hasRelatedWork W3962595 @default.
- W2358717605 hasRelatedWork W4892554 @default.
- W2358717605 hasRelatedWork W5002388 @default.
- W2358717605 hasRelatedWork W16813516 @default.
- W2358717605 isParatext "false" @default.
- W2358717605 isRetracted "false" @default.
- W2358717605 magId "2358717605" @default.
- W2358717605 workType "article" @default.